Table 2 The outcomes of CAR-T therapy with different costimulatory molecules for CLL patients in published trials
From: Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia
Signal | Target | Study | Number | Preconditioning | Source | Cell dose | ORR and CRR |
|---|---|---|---|---|---|---|---|
CD28 | CD19 | 2011.Brentjens | 8 | None (3) | Autologous | Without preconditioning: 1.2–3.0 × 107/kg | ORR 1/7 (14.3%) |
CRR 0/7 (0%) | |||||||
Cyclophosphamide (5) | With preconditioning: 0.4–1.0 × 107/kg | One died before evaluation | |||||
2012.Kochenderfer | 4 | Fludarabine + cyclophosphamide (4) | Autologous | 0.3–2.8 × 107/kg | ORR 3/4 (75.0%) | ||
CRR 1/4 (25.0%) | |||||||
2013.Cruz | 4 | None | Allogeneic | 1.5–12 × 107/m2 | ORR 1/4 (25.0%) | ||
CRR 0/4 (0%) | |||||||
2015.Kochenderfer | 4 | Fludarabine + cyclophosphamide (4) | Autologous | 1–4 × 106/kg | ORR 4/4 (100%) | ||
CRR 3/4 (75.0%) | |||||||
2015.Kochenderfer 2016.Brudno | 5 | None | Allogeneic | 0.4–3.1 × 106/kg | ORR 2/5 (40.0%) | ||
CRR 1/5 (20.0%) | |||||||
2018.Geyer | 8 | Cyclophosphamide (8) | Autologous | 3 × 106/kg, 1 × 107/kg 3 × 107/kg | ORR 2/8 (25.0%) | ||
CRR 2/8 (25.0%) | |||||||
κ | 2016. Ramos | 2 | None | Autologous | 9.1 × 107/m2 | ORR 0/2 (0%) | |
1.6 × 108/m2 | CRR 0/2 (0%) | ||||||
CD137 | CD19 | 2011.Kalos | 14 | Bendamustine (6) | Autologous | 0.14–11 × 108 | ORR 8/14 (57.1%) |
2011.Porter | Fludarabine/cyclophosphamide (3) | CRR 4/14 (28.6%) | |||||
2015.Porter | Pentostatin/cyclophosphamide (5) | ||||||
2017.Turtle | 24 | Fludarabine + cyclophosphamide (21) | Autologous | 2 × 105/kg, 2 × 106/kg | ORR 16/23 (69.6%) | ||
Fludarabine (2) | CRR 4/23 (17.4%) | ||||||
Cyclophosphamide (1) | 2 × 107/kg | One died before evaluation |